The UK Competition and Markets Authority (CMA) has issued a Statement of Objections to pharmaceutical suppliers Pfizer and Flynn Pharma against concerns of breaching UK and European competition law by selling AN epilepsy drug at an excessive price between 25 to 27 time higher than those previously charged. Pfizer, the US based pharma company, has a distribution agreement with Flynn Pharma for the sale of the said anti-epilepsy drug. CMA’s provisional view is that the companies abused a dominant position by charging “excessive and unfair”prices for phenytoin sodium capsules.